Top

BY Sarah Zizinia

Combining a 3D virtual cutting guide with a surgical navigation tool allowed MD Anderson surgeons to perform a complicated pelvic reconstruction more efficiently while increasing the anatomic accuracy and likely durability of the repair.

In this first such case, the combined technology allowed a more precise fit for an implant crafted from the patient’s fibula.

“When there is a really good fit, the survivorship of the...

A 3D image shows the initial tumor in blue, left, the surgical plan in red, and then the reconstruction with a fibula implant in green at right. Image by Materialise.

BY Clayton Boldt, Ph.D.

Cancer’s ability to evolve in response to treatment and develop resistance to available therapies is one of the most significant challenges...

BY Clayton Boldt, Ph.D.

Glioblastoma (GBM) is not among the most commonly diagnosed cancers in the U.S., but it can certainly be among the most devastating. Of the...

BY Clayton Boldt, Ph. D.

Building upon the foundational discovery that the targeted therapy poziotinib is a potent and selective inhibitor of specific EGFR and HER2 mutations in lung cancer, researchers at MD Anderson have now characterized HER2 mutation type and frequency across cancer types and found that poziotinib shows activity against the most common HER2 variants seen in cancer.

The study also reports results from a phase II clinical trial, in which...

HER2 protein structure showing the location of the drug binding pocket. Exon 19, 20 and 21 domains are colored in blue, pink and orange, respectively, with sites for common mutations labeled.

BY Clayton Boldt, Ph. D.

Results from two MD Anderson-led clinical trials indicate that targeted therapies led to significant improvements in progression-free survival...

BY Meagan Raeke

Early results from two MD Anderson studies show promising responses to neoadjuvant (pre-surgical) checkpoint inhibitors in patients with advanced...

BY Clayton Boldt

Multiple myeloma is the second most common hematological malignancy in the United States, and it’s increasing in incidence. An estimated 32,110...

BY Ron Gilmore

The addition of nivolumab to induction chemotherapy with idarubicin and cytarabine is feasible in patients with newly diagnosed acute myeloid...

BY Clayton Boldt, Ph.D.

According to the Centers for Disease Control and Prevention, the human papillomavirus is responsible for roughly 33,700 new cancer cases each...

BY Ron Gilmore

A study at The University of Texas MD Anderson Cancer Center has shed information on a novel oncogenic pathway and points to the use of BET...